On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. The first cohort of five patients enrolled in the study was treated at Temple University Hospital in Philadelphia, PA.

The study is expected to enroll up to 30 patients at several sites in the United States. This follows the FDA’s review and acceptance of the Companyﾒs investigational new drug (IND) application for the COVID-19 study.